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Antioxidant Treatment Regulates the Humoral Immune Response
during Acute Viral Infection
Katie E. Crump, P. Kent Langston, Sujana Rajkarnikar, Jason M. Grayson
Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Generation of reactive oxygen intermediates (ROI) following antigen receptor ligation is critical to promote cellular responses.How-
ever, the effect of antioxidant treatment onhumoral immunity during a viral infectionwas unknown.Micewere infectedwith lympho-
cytic choriomeningitis virus (LCMV) and treatedwithMn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP), a superoxide
dismutasemimetic, fromdays 0 to 8 postinfection.Onday 8, at the peak of the splenic response in vehicle-treatedmice, virus-specific
IgMand IgG antibody-secreting cells (ASC)were decreased 22- and 457-fold inMnTBAP-treated animals. By day 38, LCMV-specific
IgGASCwere decreased 5-fold in the bonemarrowof drug-treatedmice, and virus-specific antibodieswere of lower affinity. Interest-
ingly, antioxidant treatment hadno effect on the number of LCMV-specific IgGmemoryB cells. In addition to decreases inASC,
MnTBAP treatment decreased the number of functional virus-specificCD4T cells. The decreased numbers of ASCobserved onday 8
in drug-treatedmicewere due to a combination of Bim-mediated cell death anddecreased proliferation. Together, these data demon-
strate that ROI regulate antiviral ASC expansion andhave important implications for understanding the effects of antioxidants on
humoral immunity during infection and immunization.
Antibodies are a critical component of the immune system’sdefense to infectious microorganisms. In order to initiate an
antibody response to a pathogen, naïve B cells must first be acti-
vated through recognition of antigen by the B cell receptor (BCR).
Following antigen stimulation, activated B cells enlist cognate
CD4 T cell help to stimulate clonal expansion (1). Upon activa-
tion and proliferation, B cells embark on two distinct differentia-
tion pathways (2). First, the initial production of antibody to a
pathogen is accomplished through the differentiation of activated
B cells into extrafollicular plasmablasts (3). These short-lived cells
are essential in generating low-affinity antibodies early during the
infection. However, to generate long-lived humoral immunity,
activated B cells must migrate to the germinal center, undergo
affinity maturation by somatic hypermutation, and undergo iso-
type switching to produce memory B cells or antibody-secreting
plasma cells (ASC) (3). Memory B cells are long-lived and rapidly
respond to pathogen re-encounter by proliferating and differen-
tiating into ASC (4). High-affinity, long-lived ASC migrate to the
bone marrow, where they continuously secrete antibody and per-
sist for a year or more in mice (5) and decades in humans (6).
Therefore, determining the factors that modulate these pathways
is critical not only for understanding the generation and mainte-
nance of serological memory but also for optimizing vaccines and
therapeutics for autoimmune disorders.
Following antigen receptor ligation, reactive oxygen interme-
diates (ROI) are generated and required for B cell function (7–9).
Previous work has demonstrated that antioxidant treatment de-
creased lipopolysaccharide (LPS)-induced B cell proliferation in
vitro (10, 11). Singh and colleagues (12) provided the first piece of
evidence that ROI produced following B cell activation are critical
for calcium flux and amplification of early BCR-induced signals.
Consistent with this idea, B cells deficient in ROI-generating pro-
teins exhibit decreased Syk and Akt phosphorylation following
activation (7). Additionally, we have previously shown that the
first oxidation product of cysteine, sulfenic acid, is a critical oxi-
dative modification required for the induction of capacitative cal-
cium entry and maintenance of tyrosine phosphorylation follow-
ing BCR ligation (8). Furthermore, ROI have also been implicated
in the humoral immune response in vivo. Studies using loss-of-
function mutants in the voltage-gated proton channel HVCN1 by
Capasso et al. (7) show that ROI act as positive regulators in B cell
responses to both T-cell-dependent and -independent model an-
tigens. Taken together, these findings suggest ROI generated fol-
lowing antigen receptor ligation act as positive mediators of B cell
responses. In contrast, other studies suggest that the overproduc-
tion of ROI associated with chronic viral infections, autoimmune
disorders, and cancer plays a role in lymphocyte dysfunction (13–
15). Due to the potential role of ROI in pathology, antioxidant
supplementation has risen, with 48% of people ingesting one daily
(16). The contribution of ROI and antioxidant ingestion to the
humoral immune response to a physiological stimulus such as a
viral infection is unknown.
In this study, we examined the effect of antioxidant treatment
on humoral immune responses during acute viral infection. Mice
were treated with Mn(III)tetrakis(4-benzoic acid)porphyrin chlo-
ride (MnTBAP), a superoxide dismutase mimetic, from days 0 to
8 during acute lymphocytic choriomeningitis virus (LCMV) in-
fection. We found that early (day 5) expansion of virus-specific
IgM and IgG ASC was not affected, but at the peak of the splenic
response, MnTBAP-treated mice had 22- and 457-fold-lower
numbers of virus-specific IgM and IgG ASC, respectively. When
the long-lived ASC in the bone marrow were assessed at day 38,
LCMV IgG ASC were found to be decreased 5-fold in the drug-
treated mice. Interestingly, the number of virus-specific IgG
memory B cells was not affected. In addition, MnTBAP treatment
decreased the number of polyfunctional virus-specific CD4 T
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cells. The decrease in virus-specific ASC and CD4T cells was due
to a combination of Bim-mediated cell death and decreased pro-
liferation. Together, these data demonstrate an important role for
ROI in controlling the expansion of antigen-specific ASC gener-
ated during viral infection and provide a better understanding of
how high-dose antioxidant supplementation could affect hu-
moral immune responses following infection and immunization.
MATERIALS AND METHODS
Mice, virus, and infections. Female C57BL/6 mice, 6 to 8 weeks old, were
purchased from the National Cancer Institute (Frederick, MD). Bim
(Bcl2l11)/ mice were purchased from Jackson Laboratories. Mice were
infected with 2  105 PFU of LCMV Armstrong intraperitoneally and
used at the time points indicated below. Virus was grown and quantitated
as previously described (17). All studies were approved by the Institu-
tional Animal Care and Use Committee (IACUC) of Wake Forest School
of Medicine.
MnTBAP treatment. MnTBAP treatment was performed as previ-
ously described (18). Briefly, MnTBAP (Calbiochem) was dissolved in 0.1
N NaOH as a 6-mg/ml stock and diluted in sterile phosphate-buffered
saline (PBS) to give an intraperitoneal dose of 5 mg/kg of body weight.
Four hours later, mice were infected with LCMV Armstrong. A mainte-
nance dose was administered to the mice every 24 h for the duration of
treatment.
Cell isolation. Spleens were removed from mice following cervical
dislocation. After the spleen was teased apart on a wire mesh screen, red
blood cells were osmotically lysed using ACK lysis buffer (Lonza). Spleno-
cytes were resuspended in complete medium containing RPMI 1640 sup-
plemented with 10% fetal calf serum (FCS; HyClone), L-glutamine
(HyClone), penicillin-streptomycin (Cellgro), nonessential amino acids
(Gibco), and 2-mercaptoethanol (Gibco). To isolate bone marrow cells, both
femurs were flushed with complete medium. Red blood cells were osmoti-
cally lysed as described above, and then cells were washed and counted.
Surface and intracellular staining. In this study, the following anti-
bodies were used: rat anti-mouse CD4-peridinin chlorophyll protein
(CD4-PerCP), rat anti-mouse CD44-allophycocyanin (CD44-APC), rat
anti-mouse CD62L-APC-Cy7, rat anti-mouse CXCR5-biotin, rat anti-
mouse GL7-fluorescein isothiocyanate (GL7-FITC), rat anti-mouse
CD138-phycoerythrin (CD138-PE), rat anti-mouse B220-APC-Cy7, rat
anti-mouse B220-APC, rat anti-mouse CD19-APC, hamster anti-mouse
PD-1-PE, hamster anti-mouse CD95-PE, anti-mouse CD150-Pacific blue
surface, anti-mouse IgD-eFluor 450, rat anti-mouse gamma interferon
(IFN-)-FITC, rat anti-mouse tumor necrosis factor alpha (TNF-)-PE,
and rat anti-mouse interleukin 2 (IL-2)-APC. All antibodies were pur-
chased from BD Pharmingen except for CD19, IgD (eBioscience), and
CD150 (BioLegend). Surface staining was performed by incubating cells
in a 1:100 dilution of antibody in 2% FACS buffer (PBS plus 2% FCS) for
30 min on ice. Cells were washed three times with FACS buffer and fixed in
2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO). After three washes,
intracellular cytokine staining was performed using the BD Cytofix/Cy-
toperm kit according to the manufacturer’s protocol. Samples were acquired
on a BD FACSCanto instrument and analyzed using FlowJo software (Tree-
Star, San Francisco, CA).
For CXCR5, secondary stains were performed. Briefly, cells were in-
cubated in a 1:100 dilution of CXCR5-biotin in FACS buffer for 30 min at
room temperature. Following three washes with FACS buffer, cells were
stained with PE-Cy7-labeled streptavidin (Invitrogen) for 30 min on ice.
Cells then were washed three times with FACS buffer and fixed in 2%
paraformaldehyde.
Intracellular IL-21 staining was performed following surface staining
as previously described by Johnston et al. (19). Briefly, samples were fixed
and permeabilized using BD Cytofix/Cytoperm and incubated with re-
combinant human IL-21 R subunit Fc chimera (R&D Systems) for 60 min
on ice. After two washes, samples were stained with APC-conjugated
F(ab=)2 fragment goat anti-human IgG Fc for 30 min on ice. Samples
were washed twice with PermWash buffer and twice with FACS buffer and
then fixed in 2% paraformaldehyde.
Enzyme-linked immunospot (ELISPOT) analysis. IgM and IgG
LCMV-specific ASC were quantified using nitrocellulose bottom 96-well
plates (Millipore, Billerica, MA) coated with LCMV-infected BHK cell
lysate as previously described (20). Briefly, coated plates were washed with
PBS containing 0.1% Tween 20 (PBS-T) followed by three washes with
PBS. The plates were blocked with complete medium for 1 h at room
temperature. Threefold dilutions of cells were incubated on the blocked
plate for 5 h at 37°C. Following washes, samples were incubated with
biotin-conjugated goat anti-mouse IgM() or IgG() (Invitrogen) for a
minimum of 12 h at 4°C. The plates were washed with PBS-T and incu-
bated with horseradish peroxidase-conjugated avidin-D (Vector Labora-
tories) for 1 h at room temperature. After washes, the plates were devel-
oped using hydrogen peroxide chromogen substrate. The membranes
were dried, and spots were enumerated.
Antibody titer. At the time points indicated below, serum from in-
fected mice was collected, and the LCMV-specific antibody titer was
quantified by enzyme-linked immunosorbent assay (ELISA) as previously
described (17). The LCMV-specific antibody titer is expressed as the re-
ciprocal of the highest dilution showing a reading for optical density at
492 nm (OD492) greater than three times the average OD492 reading of
background levels.
Antibody affinity. LCMV-specific IgG affinity was determined by a
modification of an ELISA method previously described by Bates et al. (21).
Briefly, 96-well plates were coated overnight with LCMV-infected BHK
cell lysate. The plates were washed three times with PBS containing 0.05%
Tween 20 and blocked with 200l of PBS supplemented with 10% FCS for
2 h at room temperature. Following three washes, serum samples were
added to the wells and incubated overnight at 4°C. The wells were washed
five times, and various concentrations of sodium thiocyanate (NaSCN) were
added to the plate for 15 min. Samples were washed and incubated with
horseradish peroxidase-conjugated anti-mouse IgG (SouthernBiotech) for
2 h at room temperature. Wells were developed with tetramethylbenzi-
dine (Sigma-Aldrich) for 30 min. The reaction was stopped with 2 N
H2SO4, and absorbance was measured at 450 nm. The affinity was defined
as the concentration of NaSCN required to produce a 50% reduction in
absorbance. Preliminary studies were conducted in order to determine
that the optimal serum dilution was 1:51,200. At this dilution, no protein
precipitate formed during the development of the assay.
Quantification of LCMV-specific memory B cells. LCMV-specific
memory B cells were quantified by a modification of a limiting dilution
method described previously (22). Briefly, 5-fold dilutions of splenocytes
from infected mice were tested in 12-well replicates. Splenocytes were
cultured in a 96-well flat-bottom plate for 5 days at 37°C in the presence of
1 106 irradiated (1,200 rads) sex-matched feeder splenocytes, 0.6 g of
R595 lipopolysaachride (Alexis Biochemicals), and 20 l of concanavalin
A supernatant in complete medium for a total volume of 200 l. After 5
days of polyclonal stimulation, cells were harvested, washed, and trans-
ferred to a nitrocellulose bottom 96-well plate coated with LCMV-in-
fected BHK cell lysate. LCMV-specific ELISPOT assays were performed as
previously described (20).
BrdU labeling. Mice were administered 0.8 mg/ml of bromodeoxyu-
ridine (BrdU) in the drinking water beginning at day 6 of LCMV Arm-
strong infection. BrdU staining was performed as previously described by
Tebo et al. (23). Samples were acquired on a BD FACSCanto instrument
and analyzed using FlowJo software.
Statistical analysis. Data from vehicle- and MnTBAP-treated mice
were analyzed using a two-tailed Student t test. A P value of 0.05 was
considered significant.
RESULTS
Administration of MnTBAP decreases ROI levels in activated/
memory phenotype B cells during an acute viral infection. Pre-
vious studies have determined that superoxide generated follow-
Crump et al.
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ing naïve BCR ligation is critical for cysteine oxidation (8) and
signal transduction pathways (7). Therefore, we hypothesized that
following in vivo activation, B cells generate ROI, which regulate
their responses. To address this hypothesis, we wanted to deter-
mine if ROI levels increase in B cells following in vivo activation
with a physiological stimulus such as viral infection. Superoxide
production was assessed using the fluorescent dye dihydro-
ethidium (HE), a cell-permeant dye that upon oxidation interca-
lates into DNA. Unactivated B cells were identified as B220 IgD
cells, while activated/memory phenotype B cells were identified as
B220 IgDlo cells (19). Figure 1A demonstrates that unactivated
B cells from naïve mice contain basal levels of superoxide, with
a mean fluorescence intensity (MFI) of 3,225. However, on day
8 after LCMV infection, superoxide levels in activated/memory
phenotype B cells had increased to an MFI of 6,377 (Fig. 1B). In
contrast, when we assessed the superoxide production in MnTBAP-
treated mice on day 8 postinfection, superoxide levels in activated/
memory phenotype B cells were found to be modestly reduced, to
an MFI of 5,579 (Fig. 1B). When data from multiple mice were
normalized to unactivated, naïve B cells, treatment with MnTBAP
modestly reduced the levels of superoxide in activated/memory
phenotype B cells (fold increases were 1.90 for vehicle-treated cells
and 1.50 for MnTBAP-treated cells) (Fig. 1C). Thus, superoxide
production increases in B cells following in vivo activation during
acute viral infection, and MnTBAP treatment lowers the level of
ROI produced.
The expansion of virus-specific antibody-secreting cells, but
not memory B cells, is reduced in MnTBAP-treated mice. Be-
cause ROI production following receptor ligation promotes signal
transduction, we hypothesized that lowering ROI with MnTBAP
would decrease B cell responses following viral infection. To ad-
dress this hypothesis, we administered the antioxidant MnTBAP
to mice infected with LCMV Armstrong from days 0 to 8 postin-
fection. In both vehicle- and MnTBAP-treated mice, LCMV Arm-
strong induces an acute infection that peaks to similar levels at day
3 and is cleared in 9 to 10 days (18). It also induces a large expan-
sion of B cells that differentiate into antigen-specific ASC which
secrete virus-specific antibody for the life of the animal (5). The
initial ASC response occurs in the spleen at day 8 postinfection;
however, by day 30, 90% of the cells will home to the bone marrow
(5). Early during infection, on day 5, vehicle- and drug-treated
mice had similar numbers of virus-specific IgM and IgG ASC in
the spleen (Fig. 2A and B). At the peak of the response, on day 8
postinfection, antigen-specific IgM and IgG ASC were decreased
22- and 457-fold, respectively, compared to levels in control mice.
Virus-specific ASC located in the blood and lymph nodes were
also reduced in the MnTBAP-treated mice, suggesting that the
cells were not localized to a different tissue (data not shown). ASC
were lower at day 10 postinfection; however, the virus-specific
IgM and IgG ASC responses in the spleen were similar in the two
groups by day 15 postinfection. When the long-lived LCMV-spe-
cific ASC population was analyzed on day 38 postinfection, there
was a significant reduction in the IgG (5-fold) but not the IgM
response in MnTBAP-treated mice (Fig. 2C and D). Additionally,
we detected similar kinetics and reductions in the polyclonal plas-
mablast (CD19hi-int B220hi-int CD138 IgD) pool between vehi-
cle- and MnTBAP-treated mice (Fig. 2E). Because virus-specific
ASC were decreased with antioxidant treatment, we determined
whether total IgG ASC was altered. After 8 days of vehicle or
MnTBAP treatment of uninfected mice, there was no significant
FIG 1 Treatment with MnTBAP reduces superoxide levels in activated B cells.
Splenocytes from naïve C57BL/6 mice (A) or those infected with 2 105 PFU
of LCMV Armstrong 8 days prior and treated with either vehicle or 5 mg/kg of
MnTBAP (B) were incubated with HE and stained with anti-B220 and anti-
IgD antibodies. The HE levels are plotted as histograms, with the MFI indi-
cated in the upper right corners of the plots. (C) Quantification of HE levels in
activated/memory phenotype B cells from multiple mice was done by dividing
the HE MFI of activated memory phenotype B cells (B220 IgDlo) in infected
mice by the HE MFI of unactivated B cells (B220 IgDhi) in naïve mice. Six
mice were analyzed in a minimum of two independent experiments. *, signif-
icant difference between vehicle- and MnTBAP-treated mice; P 0.05.
Antioxidants and Antiviral Humoral Immunity
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difference in the number of polyclonal ASC (Fig. 2F). During in-
fection, the total number of IgG-secreting ASC increased to
1.72  106 in vehicle-treated mice, and this was reduced 4-fold
following MnTBAP administration. Taken together, these data
suggest that MnTBAP is not inherently cytotoxic to ASC.
In addition to examining the number of LCMV-specific ASC,
we determined whether MnTBAP treatment affected the genera-
tion of virus-specific IgG memory B cells. These quiescent and
recirculating cells respond rapidly to antigen re-encounter by dif-
ferentiating into virus-specific ASC (5). Interestingly, the num-
bers of antigen-specific IgG memory B cells were equivalent be-
tween the two groups at day 38 postinfection (Fig. 2G). Therefore,
treatment with MnTBAP reduces the number of antigen-specific
ASC while having no effect on the generation of memory B cells.
MnTBAP treatment reduces the titer and affinity of virus-
specific IgG antibody. The ability of ASC to produce antibodies is
often the immune system’s first line of defense to an invading
pathogen. As shown in Fig. 2H, we compared the virus-specific
FIG2 MnTBAP treatment results in decreased expansion of virus-specific IgM and IgG ASC during acute viral infection. C57BL/6 mice were treated with vehicle
or 5 mg/kg of MnTBAP. Four hours later, mice were infected with 2  105 PFU of LCMV Armstrong. A maintenance dose of vehicle or MnTBAP was
administered every 24 h for 8 days. At the indicated time points, mice were sacrificed and the numbers of virus-specific IgM (A and C) and IgG (B and D) ASC
in the spleen and bone marrow were quantitated by ELISPOT assay. (E) Quantification of the number of plasmablasts in vehicle- and MnTBAP-treated mice
following staining with anti-B220, anti-CD19, anti-IgD, and anti-CD138. (F) Naïve or LCMV-infected mice received a daily dose of vehicle or MnTBAP every
24 h for 8 days. On day 8, mice were sacrificed and spleens were removed. The total IgG ASC were quantitated by ELISPOT assay. (G) The number of
LCMV-specific IgG memory B cells was quantified by limiting dilution assay at day 38 postinfection in vehicle- and MnTBAP-treated mice. (H) Serum
virus-specific IgG antibody titer was determined on day 38 postinfection by ELISA. The dashed line represents the limit of detection. N.D., not detectable. (I)
Affinity was determined by ELISA and was quantified as the concentration of NaSCN required to reduce the absorbance of serum virus-specific IgG by 50%. The
averages and standard deviations are shown. Five to nine mice were analyzed in a minimum of two independent experiments. *, significant difference between
vehicle- and MnTBAP-treated mice; P 0.05.
Crump et al.
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antibody titers in vehicle- and MnTBAP-treated mice at day 38
postinfection. In vehicle-treated mice, the serum LCMV-specific
IgG titer reached 10,000. When titers in MnTBAP-treated mice
were examined, they were found to be reduced to 2,500. In addi-
tion to total titer, it is critical to measure the affinity of the
antibodies generated. On day 38 postinfection, serum samples
from vehicle- and MnTBAP-treated mice were collected, and
antibody affinity was determined by the concentration of so-
dium thiocyanante (NaSCN) required to reduce the antigen-
bound antibody absorbance by 50% as measured by ELISA.
The average LCMV-specific antibody affinity from vehicle-
treated mice was 1.3 M NaSCN, while samples from MnTBAP-
treated mice had a significant reduction (0.99 M) in antibody
affinity (Fig. 2I). Thus, MnTBAP treatment reduces the affinity
and titer of LCMV-specific IgG antibody.
MnTBAP treatment decreases the number of germinal-cen-
ter B cells.Previous studies have shown that germinal center B cell
formation is critical to the differentiation of long-lived, high-af-
finity ASC (24). Because MnTBAP treatment decreased the overall
titer and affinity of the anti-LCMV antibody, we determined
whether the number of germinal center B cells was altered. Figure 3
shows that early during infection, on day 5, the numbers of ger-
minal center B cells (B220 GL7 Fas) were roughly equivalent
in the two groups of mice (1.53 105 for vehicle versus 1.14 105
for MnTBAP). However, in vehicle-treated mice, the number of
germinal center B cells expanded to 1.36  106 cells at day 8 and
remained elevated through day 15 postinfection. This result con-
trasts with that for the MnTBAP-treated mice, which had a sub-
stantial reduction in germinal B cells at days 8 and 10 postinfec-
tion. However, by day 15 postinfection, germinal center B cell
numbers in MnTBAP-treated mice reached a similar peak. By day
38 postinfection, the numbers of germinal center B cells declined
and were equivalent between the two groups. Therefore, treat-
ment with MnTBAP alters the number of germinal center B cells
and the kinetics of their formation.
Administration of MnTBAP decreases the number of func-
tional virus-specific effector andmemoryCD4Tcells.Cognate
CD4T cell help is required for effective B cell responses to T-cell-
dependent antigens such as LCMV. Because the number of virus-
specific ASC was decreased, we determined whether CD4 T cell
help was altered in MnTBAP-treated mice. To measure func-
tional CD4 T cells, we performed intracellular cytokine stain-
ing for IFN-, TNF-, and IL-2 following in vitro GP61-80
stimulation. Early during the effector response, on day 5, we
observed similar percentages of cells producing cytokines in
vehicle- and MnTBAP-treated mice (Fig. 4A and B). By day 8
postinfection, 16.03% of CD4 T cells produced only IFN-,
10.6% produced both IFN- and TNF-, and 8.35% produced
IFN- and IL-2. MnTBAP-treated mice showed a decrease in
the percentage of cells producing all cytokines such that only
2.16% produced IFN-, 1.28% produced both IFN- and
TNF-, and 1.25% produced IFN- and IL-2. Similar trends
were observed at days 10 and 15 postinfection. Analysis of the
memory phase revealed that MnTBAP mice had a decrease in
the percentage of cells producing IFN- and IL-2. In accor-
dance with the percentage data, we observed similar reductions
in the total number of functional CD4 T cells during the
effector (day 8, 13-fold) and memory (day 38, 2-fold) phases
in MnTBAP-treated mice (Fig. 4C). Furthermore, MnTBAP-
treated mice exhibited a reduction in the percentage of IFN-
cells also producing TNF- and IL-2 at day 15 (Fig. 4D and E).
Taken together, antioxidant treatment decreases the number
and polyfunctionality of antigen-specific effector and memory
CD4 T cells.
Treatment with MnTBAP decreases the number of CD4
TFH cells. Previous studies have demonstrated the requirement of
T follicular helper (TFH) cells for the development and mainte-
nance of germinal center B cells (19, 25, 26). Because the number
of germinal center B cells was significantly decreased in MnTBAP-
treated mice, we determined whether the number of TFH cells was
altered with antioxidant treatment. TFH cells were identified as
activated (CD44hi CD62Llo) CD4 T cells that express high levels
of CXCR5 and low levels of SLAM (27). Figure 5A shows that the
numbers of TFH cells were similar for vehicle- and MnTBAP-
treated mice early during infection (day 5). However, at days 8 and
10 postinfection, we detected fewer TFH cells in the drug-treated
mice relative to control mice. Similar results were observed when
we assessed TFH cells by Bcl6 and CXCR5 staining (data not
shown). Prior studies have demonstrated that TFH cells within the
germinal center (GC TFH) have a greater ability to provide help to
B cells (28, 29). Early during infection, at day 5, vehicle- and
MnTBAP-treated mice contained similar numbers of this popu-
lation in the spleen; however, by days 8 and 10 postinfection, the
numbers were significantly decreased, 8.3- and 4.6-fold, respec-
tively, in drug-treated mice (Fig. 5B). Although the numbers were
decreased at days 8 and 10 postinfection in MnTBAP-treated
mice, this population increased in drug-treated mice to levels sim-
ilar to those in the control mice by day 15 postinfection.
TFH cell-derived IL-21 is critical for proliferation and survival
of germinal center B cells, isotype switching, and ASC differenti-
ation (30, 31). In Fig. 5C, we compared the abilities of CD4 T
cells from vehicle- and MnTBAP-treated mice to produce IL-21
when stimulated with phorbol myristate acetate (PMA) and iono-
mycin in vitro. Early during infection, on day 5, MnTBAP-treated
mice had numbers of IL-21-producing CD4 T cells similar to
those of the control mice. At day 8 postinfection, the number of
functional cells was significantly reduced in the drug-treated mice
(1.28  106 for vehicle versus 1.85  105 for MnTBAP). Similar
trends were observed at day 10 postinfection. However, when we
FIG 3 MnTBAP treatment decreases the number of germinal center B cells.
C57BL/6 mice were treated with either vehicle or 5 mg of MnTBAP/kg. After 4
h, mice were infected with 2 105 PFU of LCMV Armstrong. A maintenance
dose was administered every 24 h for 8 days. At the indicated time points, mice
were sacrificed, the spleen was removed, and cells were stained with anti-B220,
anti-GL7, and anti-Fas. The numbers of B220 GL7 Fas germinal center B
cells were quantitated, and the averages and standard deviations are shown.
Five to six mice were examined in a minimum of two independent experi-
ments. *, significant difference between vehicle- and MnTBAP-treated mice;
P 0.05.
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assessed the cells on day 15 postinfection, we found that the num-
bers of CD4 T cells producing IL-21 were similar for the two
groups. Taken together, these results demonstrate that antioxi-
dant treatment decreases the number and function of TFH cells at
days 8 and 10 postinfection. However, this loss was temporary,
because MnTBAP-treated mice recovered by day 15 postinfection.
Decreased expansion of virus-specific ASC andCD4T cells
is due to decreased proliferation and increased Bim-mediated
cell death.Cell number is a balance of proliferation and cell death.
While we observed similar numbers of virus-specific ASC and
CD4 T cells in vehicle- and MnTBAP-treated mice at day 5
postinfection, there was a significant reduction in drug-treated
mice by day 8. To determine whether proliferation was altered in
the MnTBAP-treated mice, we administered 0.8 mg/ml of bro-
modeoxyuridine (BrdU) in the drinking water of both groups of
mice at day 6 postinfection. A mouse receiving water alone was
used as a control. This time point was selected because it was an
intermediate point between days 5 and 8 postinfection, when we
observed a decrease in cell number. Spleens were harvested from
mice at day 7 postinfection and stained for surface markers and
FIG 4 Decreased cytokine production by virus-specific CD4 T cells from mice treated with MnTBAP. C57BL/6 mice were treated with either vehicle or 5 mg
of MnTBAP/kg. After 4 h, mice were infected with 2 105 PFU of LCMV Armstrong. A maintenance dose was administered every 24 h for 8 days. At the indicated
time points, mice were sacrificed and the spleen was removed. Splenocytes were stimulated with GP61-80 peptide for 5 h at 37°C. Following stimulation, cells
were stained with anti-CD4, anti-IFN-, and either anti-TNF- (A) or anti-IL-2 (B). The dot plots are gated on CD4 T cells, and the numbers in each plot
indicate the percentage of CD4 T cells present in the quadrants. (C) The number of IFN- CD4 T cells was quantitated in the spleen. For each virus-specific
CD4T cell population, the percentage of IFN- cells that produced TNF- (D) and IL-2 (E) was determined. The averages and standard deviations are plotted.
Five to six mice were analyzed in a minimum of two independent experiments. *, significant difference between vehicle- and MnTBAP-treated mice; P 0.05.
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intracellular BrdU. In vehicle-treated mice, 38.6% of plasmablasts
were BrdU, compared to 13.9% in MnTBAP-treated mice
(Fig. 6A). Similar trends were observed in the activated CD4 T
cell compartment (47.3% for vehicle versus 16.3% for MnTBAP)
(Fig. 6B). Data from multiple mice revealed a significant decrease
in the percentages of plasmablasts and activated CD4 T cells that
were BrdU in the MnTBAP-treated mice (Fig. 6C). These results
indicate that plasmablasts and activated CD4 T cells in MnT-
BAP-treated mice underwent reduced proliferation.
In addition to measuring proliferation, we assessed the contri-
bution of cell death by examining whether mice deficient in Bim
(Bcl2l11), a BH3-only proapoptotic member of the Bcl-2 super-
family, could rescue the cell number defect we observed in the
MnTBAP-treated mice at day 8 postinfection. Wild-type and
Bcl2l11/ mice were treated with vehicle or MnTBAP and then
infected with LCMV Armstrong. The humoral and cell-mediated
responses were measured at day 8 postinfection. As we previously
observed, wild-type MnTBAP-treated mice had significant de-
creases in the numbers of splenic virus-specific IgM and IgG ASC
(Fig. 6D) and functional antigen-specific CD4 T cells (Fig. 6E)
compared to vehicle-treated mice. When Bcl2l11/ mice were
examined, both the IgM and IgG virus-specific ASC were found to
be increased in vehicle-treated mice compared to the levels ob-
served in wild-type animals. Strikingly, loss of Bim rescued much
of the decrease in ASC observed at day 8 in MnTBAP-treated mice.
Similar trends were observed when we analyzed the number of
antigen-specific CD4 T cells (Fig. 6F). Since the loss of Bim res-
cued most of the antigen-specific ASC and CD4 T cells in
MnTBAP-treated mice, we wanted to determine whether viral
replication was altered. Similar to our prior studies (18), we ob-
served that wild-type vehicle-treated mice had viral titers of 1.5
104 PFU/g in their spleens at day 8 postinfection. This contrasted
with findings for MnTBAP-treated wild-type mice, in which viral
titers were 3.8 105 PFU/g. Treatment with MnTBAP delays viral
clearance from day 9 to 10 postinfection in wild-type mice (18).
When vehicle- and MnTBAP-treatedBcl2l11/mice were exam-
ined, viral titers were found to be 3.2  104 and 5  104 PFU/g,
respectively (Fig. 6G). Importantly, titers were not significantly
altered with treatment in Bcl2l11/mice, demonstrating that the
rescue in LCMV-specific ASC was not due to differences in viral
load. Taken together, these results demonstrate that the alteration
in antigen-specific ASC and activated CD4 T cells in drug-
treated mice is due to a combination of decreased proliferation
and increased cell death.
DISCUSSION
In this study, we utilized the antioxidant MnTBAP to examine the
role of ROI in the humoral immune response during a viral infec-
tion. Here, we report five novel observations. First, in response to
viral infection, activated/memory phenotype B cells increased
their levels of ROI. Second, antioxidant treatment reduced prolif-
eration and increased Bim-mediated cell death of virus-specific
IgM and IgG ASC during the effector phase. Third, antioxidant
treatment decreased the number and functionality of virus-spe-
cific effector and memory CD4 T cells. Fourth, MnTBAP treat-
ment decreased the affinity of the anti-LCMV IgG antibody at day
38 postinfection. Fifth, antioxidant treatment had no effect on the
number of virus-specific IgG memory B cells generated. Taken
together, these results demonstrate that ROI generated in re-
sponse to an acute viral infection are critical in controlling both
the antiviral humoral and CD4 T cell responses.
What are the roles of ROI in B cell responses? Prior work
FIG 5 Reduced number of functional TFH cells in mice treated with MnTBAP during an acute viral infection. C57BL/6 mice were treated with either vehicle or
5 mg of MnTBAP/kg. After 4 h, mice were infected with 2 105 PFU of LCMV Armstrong. A maintenance dose was administered every 24 h for 8 days. At the
indicated time points, mice were sacrificed and the spleen was removed. Splenocytes were stained with anti-CD4, anti-CD44, antiCD62L, and anti-CXCR5 and
anti-SLAM (A) or anti-GL-7 (B). The numbers of TFH cells (A) and germinal center (GC) TFH cells (B) were quantitated, and the averages and standard deviations
are shown. (C) To determine the effect of MnTBAP administration on IL-21 production by CD4 T cells, mice were sacrificed at the indicated time points and
stimulated with PMA and ionomycin for 4 h at 37°C. Following stimulation, cells were stained with anti-CD4 and IL-21R. The number of IL-21 CD4 T cells
was quantitated in the spleen, and the averages and standard deviations are shown. Five to six mice were analyzed in a minimum of two independent experiments.
*, significant difference between vehicle- and MnTBAP-treated mice; P 0.05.
Antioxidants and Antiviral Humoral Immunity
March 2013 Volume 87 Number 5 jvi.asm.org 2583
 o
n
 O
ctober 12, 2016 by NO
VA SO
UTHEASTERN UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
from our laboratory and others has demonstrated that ROI are
generated in vitro following BCR ligation by antibodies (7–9)
or antigen (8). Here, we extend these studies, demonstrating
for the first time that ROI are elevated in activated B cells
directly ex vivo following acute viral infection. There have been
conflicting reports regarding the role of these molecules in B
cell responses. Addition of antioxidants, which lower ROI, de-
creases B cell proliferation in vitro. This suggests that ROI act in
a positive manner to promote B cell proliferation. The role of
ROI in B cell responses in vivo is less clear. Richards and Clark
(9) utilized mice deficient in the gp91 subunit of the NADPH
oxidase complex and demonstrated that T-cell-independent
responses to model antigens were increased, while T-cell-de-
pendent responses were unaffected. These results suggest that
superoxide and other ROI negatively regulate responses. Using
HVCN1-deficient mice, which have decreased ROI produc-
tion, Capasso and colleagues (7) demonstrated that T-cell-de-
pendent responses were decreased following 4-hydroxy-3-ni-
trophenyl acetyl-keyhole lympet hemocyanin (NP-KLH)
immunization. This supports a positive role for ROI in pro-
moting B cell responses in vivo. We addressed the role of ROI in
a controlled window from days 0 to 8 postinfection through
antioxidant administration. Directly ex vivo, we observed a
22% decrease in ROI levels in activated B cells and a 457-fold
decrease in LCMV-specific IgG-secreting ASC by day 8. Al-
though we were able to modestly reduce ROI in B cells, it is
possible that decreasing ROI in other cell types could contrib-
ute to the effects we observed. Indeed, in our prior studies of
antioxidant treatment on CD8 T cell responses (18), we dem-
onstrated that MnTBAP treatment lowered ROI in activated T
FIG 6 Reduced ASC and CD4 T cells in MnTBAP-treated mice are due to decreased proliferation and increased Bim-mediated cell death. C57BL/6 mice were
treated with either vehicle or 5 mg of MnTBAP/kg. After 4 h, mice were infected with 2 105 PFU of LCMV Armstrong. A maintenance dose was administered
every 24 h for 8 days. (A) Proliferation was assessed by giving the mice BrdU (0.8 mg/ml) in their drinking water beginning at day 6 postinfection. Mice were
sacrificed on day 7 postinfection, and spleens were harvested. Splenocytes were stained with anti-BrdU, anti-CD138 anti-B220, anti-CD19, and anti-IgD (A) or
with anti-BrdU, anti-CD4, and anti-CD44 (B). The plots are gated on B220hi-int CD19hi-int IgD CD138 plasmablasts (A) or CD4 CD44hi (B) cells. The
numbers in the plots indicate the percentages of plasmablast or activated CD4T cells that are BrdU. The averages and standard deviations are plotted in panel
C. C57BL/6 and Bcl2l11/ mice were treated with either vehicle or 5 mg of MnTBAP/kg and infected as described previously. Mice were sacrificed at day 8
postinfection, and the spleens were removed. The numbers of antigen-specific IgM (D) and IgG (E) ASC were quantitated by ELISPOT assay. (F) Splenocytes
were stimulated with GP61-80 peptide for 5 h at 37°C. Following stimulation, cells were stained with anti-CD4 and anti-IFN-. The number of IFN- CD4
T cells was quantitated in the spleen. (G) Viral titers in the spleens of wild-type (WT) and Bcl2l11/ mice were determined by plaque assay on day 8
postinfection. The averages and standard deviations are shown. Four to six mice were analyzed in a minimum of two independent experiments. *, significant
difference between vehicle- and MnTBAP-treated mice; P 0.05.
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cells. Interestingly, our data presented here, along with our
prior studies of CD8 T cells (18), demonstrate that the initial
phase of the antiviral response (5 days) is refractory to the
effects of antioxidants. This contrasts with in vitro studies in
which activation and early proliferation are suppressed. One
potential explanation is that in vitro, superphysiological (mill-
imolar) concentrations of antioxidant are utilized to suppress
activation. In vivo, it may take several days to reach a concen-
tration of antioxidant sufficient to alter responses. Taken to-
gether, the decreased LCMV-specific ASC we observed in
MnTBAP-treated mice is consistent with a model in which ROI
are positive regulators of B cell responses in vivo.
How do ROI positively regulate humoral immune responses in
vivo? In this study, we observed decreases in LCMV-specific IgG
ASC during both the effector and memory phases. Our BrdU in-
corporation experiments demonstrate that part of the expansion
defect is due to decreased proliferation. Multiple checkpoints in
the cell cycle are regulated by ROI, including the G1/S phase and
G2/M transitions (32). Cyclin D1, a critical regulator of the G0/G1
transition, is sustained when Nox enzymes are overexpressed un-
der low-serum conditions (33). Treatment with MnTBAP, which
lowers superoxide, could lower cyclin D1 levels and decrease the
expansion of both antiviral ASC and CD4T cells. Similarly, stud-
ies by Piganelli and colleagues (34) demonstrated that treatment
with AEOL-10113, a superoxide dismutase mimetic, reduced
CD4 T cell proliferation in a diabetes model. Our results extend
these findings to an acute infectious disease model and show that
expansion of TFH cells is also inhibited by antioxidants. In addi-
tion to decreased proliferation, infection of Bim-deficient mice
demonstrates that cell death is a major contributor to the expan-
sion defect in ASC of MnTBAP-treated mice. What are the mech-
anisms by which Bim-mediated cell death is increased with drug
treatment? Bim exerts prodeath effects through interactions with
prosurvival proteins such as Bcl-2 and Mcl-1. Importantly, we did
not observe differences in Bcl-2 levels in activated B cells in
MnTBAP-treated mice (data not shown). Previous studies with
multiple cell types have demonstrated that the mitogen-activated
protein (MAP) kinase cascade is redox regulated (35–39). Addi-
tionally, it is well documented that MAP kinase-mediated phos-
phorylation of BimEL and its subsequent proteosomal degradation
are critical to B and T cell survival upon stimulation (40). There-
fore, alterations in MAP kinase signaling in the presence of
MnTBAP could decrease BimEL phosphorylation, increasing its
stability and rendering cells more susceptible to death. Lastly, our
observations of decreased numbers of antigen-specific ASC, but
not memory B cells, in MnTBAP-treated mice are similar to ob-
servations following antigen immunization of XBP-1/ mice
(41). Prior studies have clearly documented that oxidation of
transcription factors such as NF-B promotes DNA binding (42,
43). Thus, XBP-1 or other transcription factors known to be crit-
ical for ASC generation might be highly sensitive to antioxidants
because of potential oxidation sites.
Because of their roles in multiple cell types, there is interest in
manipulating ROI for therapeutic benefit. Previous studies deter-
mining the efficacy of antioxidants in various disorders, including
coronary artery disease and nephropathy, have included adminis-
tration of 600 mg ofN-acetylcysteine to patients (44, 45). Based on
this dosage, patients typically ingest 5 to 6 mg per kilogram,
which is comparable to the amount of MnTBAP we used in this
study. A recent study documented that vitamin C, -tocopherol,
carotenes, selenium, and flavonoids are the most commonly in-
gested antioxidants in the United States (16). These common an-
tioxidants are beneficial in the treatment and prevention of
chronic disorders. For example, there is an inverse relationship
between 	-carotene and vitamin C ingestion and the incidence of
breast cancer in premenopausal women (46, 47). Additionally,
studies suggest that diets rich in flavonoids reduce the risk of car-
diovascular disease in humans and rodent models (48, 49). Due to
positive effects in various disease models, there are currently 1,986
clinical trials using antioxidants (www.clinicaltrials.gov). How-
ever, while antioxidant ingestion may play a role in the prevention
of chronic disorders, our results have important implications for
supplementation during acute immune responses. Our study
demonstrates that antioxidant with superoxide dismutase activity
has a negative effect on virus-specific ASC, antibody titer, and
affinity and suggest that antioxidant supplements should be sus-
pended during infection and immunization.
In conclusion, we demonstrate that treatment with the antiox-
idant MnTBAP reduces the expansion of virus-specific antibody-
secreting cells through decreased proliferation and increased cell
death during the effector phase. These effects were also evident
during the memory phase, in which the number of LCMV-specific
ASC was decreased in the bone marrow and the overall antibody
titer and affinity were lower. In addition to effects on B cells, an-
tioxidant treatment decreased the expansion of virus-specific ef-
fector and memory CD4 T cells. Our results demonstrate that
ROI positively regulate antibody-secreting cell responses during
acute viral infection and suggest that antioxidant treatment could
benefit diseases in which inappropriate generation of these cells
occurs.
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